Photo of Anita K. Wagner,  PharmD, MPH, DrPH

Anita K. Wagner, PharmD, MPH, DrPH

Harvard Medical School

Harvard Medical School
Phone: (617) 867-4956
Fax: (617) 867-4276


awagner@hms.harvard.edu

Photo of Anita K. Wagner,  PharmD, MPH, DrPH

Harvard Medical School
Phone: (617) 867-4956
Fax: (617) 867-4276


awagner@hms.harvard.edu

Member Summary Video
Visualize Collaborations

Anita K. Wagner, PharmD, MPH, DrPH

Harvard Medical School

EDUCATIONAL TITLES

  • Associate Professor, Population Medicine, Harvard Medical School
  • Co-Director, DPM Center for Cancer Policy and Program Evaluation, Department of Population Medicine (DPM), Harvard Medical School
  • Co-Director, HMS Fellowship in Health Policy and Insurance Research, Department of Population Medicine (DPM), Harvard Medical School

HCC PROGRAM AFFILIATION

Research Abstract

The Center for Cancer Policy and Program Evaluation (CarPE) within the Department of Population Medicine (DPM) serves as a catalyst for rigorous and impactful policy research across the cancer care continuum by faculty in the DPM and our external collaborators. Our mission is to generate sound evidence to inform policies and programs, for use by stakeholders in the United States and elsewhere. We leverage the diverse research expertise of DPM faculty, effectively use and expand DPM’s large population-based electronic data resources, and actively collaborate with delivery system and payer partners of the DPM.

Within CarPE, Dr. Wagner conducts empirical research to generate evidence for answering ethically challenging health system questions related to new, highly-priced cancer therapeutics. Her work, frequently in large databases, evaluates impacts of insurance and other policy changes on the availability, access, affordability, and use of new cancer medicines, in the United States, China, and elsewhere.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Dottino JA, Baumann KE, Esselen KM, Costa R, Argetsinger S, Ross-Degnan D, Wagner AK. Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer. 2026; 101:102996. PubMed
  • Perez-Londoño A, Kaul S, Fleishman A, Korets R, Rayala H, Chang P, Wagner A, Bellmunt J, Olumi AF, Gershman B. Contemporary outcomes and disease burden of high-grade T1 bladder cancer. Can Urol Assoc J 2025. PubMed
  • Zhang Y, Li H, Chen J, Naci H, Wagner AK, Shi L, Guan X. Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005-2022: an observational study. BMJ Evid Based Med 2025. PubMed
  • Zhang Y, Chen D, Fu M, Shi L, Naci H, Wagner AK, Ross JS, Guan X. Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. Lancet Oncol. 2025. PubMed
  • Cherla A, Woloshin S, Wagner AK, Wouters OJ, Davis C, Mossialos E, Naci H. New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019-22. Health Aff (Millwood) 2025; 44:830-838. PubMed
  • Naci H, Shahzad M, Murphy P, Zhang Y, Costa R, Ross JS, Wagner AK. Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation. BMJ Med 2025; 4:e001934. PubMed
  • Dottino JA, Esselen KM, Costa R, Argetsinger S, Shahzad M, Ross-Degnan D, Wagner AK. Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer. Value Health 2024. PubMed
  • Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. Lancet Oncol. 2024; 25:760-769. PubMed
  • Wei Y, Zhang Y, Xu Z, Wang G, Zhou Y, Li H, Shi L, Naci H, Wagner AK, Guan X. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020. Lancet Reg Health West Pac 2024; 45:101055. PubMed
  • Shahzad M, Naci H, Esselen KM, Dottino JA, Wagner AK. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. J Pharm Policy Pract 2024; 17:2351003. PubMed
  • Zhou Y, Naci H, Chen D, Bai L, Shi L, Guan X, Wagner AK. Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021. BMJ Glob Health 2023. PubMed
  • Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data. J Glob Health 2023; 13:04083. PubMed
  • Ivama-Brummell AM, Marciniuk FL, Wagner AK, Osorio-de-Castro CGS, Vogler S, Mossialos E, Tavares-de-Andrade CL, Naci H. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis. Lancet Reg Health Am 2023; 22:100506. PubMed
  • Davis C, Wagner AK, Salcher-Konrad M, Scowcroft H, Mintzes B, Pokorny AMJ, Lew J, Naci H. Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ 2023; 380:e073711. PubMed
  • Haug NR, Wagner AK, McGlynn KA, Leonard CE, Nguyen MD, Major JM. New-onset cancer cases in FDA's Sentinel System: a large distributed system of US electronic healthcare data. Cancer Epidemiol Biomarkers Prev 2022. PubMed
  • Ferrario A, Zhang F, Ross-Degnan D, Wharam JF, Twaddle ML, Wagner AK. Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016. JCO Oncol Pract 2022. PubMed
  • Fu M, Naci H, Booth CM, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner AK. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med 2021. PubMed
  • Shahzad M, Naci H, Wagner AK. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval. JAMA Intern Med 2021. PubMed
  • Naci H, Guan X, Woloshin S, Xu Z, Wagner AK. Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs. JAMA Intern Med 2021. PubMed
  • Hughes TM, Empringham B, Wagner AK, Ward ZJ, Yeh J, Gupta S, Frazier AL, Denburg AE. Forecasting essential childhood cancer drug need: An innovative model-based approach. Cancer 2021. PubMed
  • Ferrario A, Xu X, Zhang F, Ross-Degnan D, Wharam JF, Wagner AK. Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States. JCO Oncol Pract 2021; 17:e194-e203. PubMed
  • Leopold C, Haffajee RL, Lu CY, Wagner AK. The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from Massachusetts. J Law Med Ethics 2020; 48:538-551. PubMed
  • Leopold C, Araujo-Lane C, Rosenberg C, Gilkey M, Wagner AK. Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program. Pharmacoecon Open 2019. PubMed
  • J. Frank Wharam, Fang Zhang, Christine Y. Lu, Anita K. Wagner, Larissa Nekhlyudov, Craig C. Earle, Stephen B. Soumerai, and Dennis Ross-Degnan. Breast Cancer Diagnosis and Treatment After High- Deductible Insurance Enrollment J Clin Oncol 2018; 36:1121-1127.
Hide
Member Summary Video